Abstract:Since the COVID-19 pandemic, many hospitals implemented a dual testing procedure for SARS-CoV-2 to assess the infection risk of an admitted patient. To allow for a short turn-around time, rapid antigen (Ag) testing via lateral flow tests (LFT) is combined with nucleic acid amplification testing (NAAT), requiring two nasopharyngeal swab collections. In this study, a novel, universal pathogen inactivation buffer (DNA/RNA Defend Pro (DRDP)) was evaluated for SARS-CoV-2 inactivation and simultaneous Ag and DNA/RNA stabilization. In an emergency department setting of a General Hospital in Ghent (Belgium), patients were tested for SARS-CoV-2, whereby a LFT for Ag detection (Abbott Panbio COVID-19 Ag Rapid Test) was performed in combination with sample collection for NAAT (Abbott Alinity m). Left-over buffers from LFT were diluted in DRDP to evaluate LFT and NAAT results after dilution. Thirty-six patients were included in the data analysis. Twenty-three diagnostic LFT results were available in the laboratory information system of which all corresponded with results after dilution with DRDP. When correlating NAAT results, seven out of eight positive test results were in agreement, compared to twenty-three out of twenty-five negative results. For thirty-four out of thirty-six samples, LFT and NAAT after dilution with DRDP yielded the same conclusion. Additionally, RNA stability in DRDP was demonstrated when stored for three days at room temperature. At the extreme, a sample stored in the DRDP buffer for 53 days at room temperature was still very positive (Cq 21.95). We demonstrated that, for the first time, a novel collection buffer could inactivate a pathogen (SARS-CoV-2) while also preserving antigen (for rapid antigen testing) and RNA (for molecular testing). This novel buffer holds promise for a single specimen to be used for both antigen and molecular testing in a safe working environment.

Fast In Situ Inactivation of Pathogens in Tubes by Plasma

One-PCR-tube approach for in situ DNA isolation and detection.

Escherichia Coli Inactivation in Water Using Pulsed Discharge

Retraction Note To: Methylene Blue Photochemical Treatment As a Reliable SARS-CoV-2 Plasma Virus Inactivation Method for Blood Safety and Convalescent Plasma Therapy for COVID-19

Inactivation of Bacteria in Water by a Direct-Current, Cold, Atmospheric-Pressure He/O2 Plasma Microjet

Inactivation Mechanisms of Pulsed Corona Discharge Plasma on Escherichia Coli and <i>Staphylococcus Aureus</i> Phages

Efficient inactivation of the contamination with pathogenic microorganisms by a combination of water spray and plasma-activated air

Rapid Inactivation of Biological Species in the Air Using Atmospheric Pressure Nonthermal Plasma

Effects of chemically-reductive trace gas contaminants on non-thermal plasma inactivation of an airborne virus

Inactivation of Infectious Bacteria Using Nonthermal Biocompatible Plasma Cabinet Sterilizer

Inactivating Microorganism on Medical Instrument Using Plasma Jet

Efficiency of Pathogenic Bacteria Inactivation by Non-Thermal Plasma Activated Water

Fast Bacteria Inactivation of Waste Water by Gas-liquid Plasma

Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing

Cell Transport Prompts the Performance of Low-Voltage Electroporation for Cell Inactivation

Water bath is more efficient than hot air oven at thermal inactivation of coronavirus

Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies

Mechanism of Virus Inactivation by Cold Atmospheric-Pressure Plasma and Plasma-Activated Water

Evaluation of a novel respiratory virus inactivating buffer for parallel RT-qPCR and quick antigen testing

Inactivation of Bacteria in an Aqueous Environment by a Direct‐Current, Cold‐Atmospheric‐Pressure Air Plasma Microjet

Cold Plasma, a New Hope in the Field of Virus Inactivation